1. Home
  2. PPT vs ABEO Comparison

PPT vs ABEO Comparison

Compare PPT & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Putnam Premier Income Trust

PPT

Putnam Premier Income Trust

SELL

Current Price

$3.36

Market Cap

328.3M

Sector

Finance

ML Signal

SELL

Logo Abeona Therapeutics Inc.

ABEO

Abeona Therapeutics Inc.

SELL

Current Price

$4.21

Market Cap

282.5M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
PPT
ABEO
Founded
1988
1974
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
328.3M
282.5M
IPO Year
N/A
2005

Fundamental Metrics

Financial Performance
Metric
PPT
ABEO
Price
$3.36
$4.21
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
★ $18.88
AVG Volume (30 Days)
113.8K
★ 988.9K
Earning Date
01-01-0001
11-16-2026
Dividend Yield
★ 8.84%
N/A
EPS Growth
N/A
★ 165.16
EPS
★ N/A
N/A
Revenue
N/A
★ $2,998,000.00
Revenue This Year
N/A
$804.33
Revenue Next Year
N/A
$119.68
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 258.18
52 Week Low
$3.21
$4.00
52 Week High
$3.66
$7.65

Technical Indicators

Market Signals
Indicator
PPT
ABEO
Relative Strength Index (RSI) 63.58 33.80
Support Level $3.22 N/A
Resistance Level $3.49 $5.91
Average True Range (ATR) 0.04 0.22
MACD 0.01 0.02
Stochastic Oscillator 100.00 14.40

Price Performance

Historical Comparison
PPT
ABEO

About PPT Putnam Premier Income Trust

Putnam Premier Income Trust is a closed-end fixed income fund that prominently invests in U.S. government, agency, high-yield, and international fixed income securities. The fund aims to provide high current income while preserving capital by diversifying across multiple bond markets beyond traditional benchmarks. Its portfolio includes various sectors such as investment-grade and high-yield corporate bonds, mortgage-backed securities, bank loans, and emerging market debt. Revenue for the trust is generated through interest income and capital gains from its investments in a fixed fund, which operates on the New York Stock Exchange and focuses on managing a diverse range of fixed-income assets across various countries.

About ABEO Abeona Therapeutics Inc.

Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.

Share on Social Networks: